Admittance Technologies is committed to improving the quality of life of patients with heart disease through innovative electrical engineering solutions. Admittance will accomplish this goal through the application of CardioVol™, which can interrogate the heart with electric fields, and in real-time distinguish the blood and heart muscle components of these fields. They focus on the blood signal to warn patients of impending heart failure, maximize their hearts’ ejection of blood by properly tuning the pacing of these weakened hearts, and using stroke volume to determine if VT and rapid afib are hemodynamically unstable requiring defibrillation.


Patents 12show all

  • 5
    A61B - Diagnosis
  • 4
    A61N - Electrotherapy

SEC Filings show all


Contact Information

3925 W. Braker Ln., 3rd Floor
Austin, TX 78759
United States


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2013-01-19$1,990,000Series Unknown
2015-05-29$3,896,000Series AUT Horizon FundGreen Park & Golf Ventures